Table 2. Treatment‐emergent adverse events with incidence >10% either in exenatide 5 μg or 10 μg group.
| Placebo n = 35 n (%) | Exenatide | ||
|---|---|---|---|
| 5 μg n = 72 n (%) | 10 μg n = 72 n (%) | ||
| Hypoglycemia | 8 (22.9) | 37 (51.4) | 42 (58.3) |
| Nausea | 3 (8.6) | 18 (25.0) | 26 (36.1) |
| Blood glucose decreased | 4 (11.4) | 10 (13.9) | 18 (25.0) |
| Vomiting | 1 (2.9) | 3 (4.2) | 12 (16.7) |
| Constipation | 1 (2.9) | 10 (13.9) | 11 (15.3) |
| Nasopharyngitis | 8 (22.9) | 8 (11.1) | 9 (12.5) |
| Stomach discomfort | 1 (2.9) | 7 (9.7) | 9 (12.5) |
| Appetite loss | 1 (2.9) | 7 (9.7) | 9 (12.5) |
| Anorexia | 1 (2.9) | 2 (2.8) | 8 (11.1) |
| Diarrhea | 2 (5.7) | 8 (11.1) | 4 (5.6) |